Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Everest Medicines Ltd. ( (HK:1952) ) has shared an update.
Everest Medicines Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The board also oversees three committees: audit, remuneration, and nomination, with specific directors assigned to each committee. This announcement provides clarity on the leadership structure of the company, potentially impacting its governance and strategic direction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$46.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Average Trading Volume: 3,418,931
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.29B
Learn more about 1952 stock on TipRanks’ Stock Analysis page.